H.C. Wainwright analyst Joseph Pantginis has revised the price target for Celldex (CLDX, Financial), lowering it from $80 to $50. Despite the adjustment, the analyst maintains a Buy rating on the stock. This decision follows the company's first-quarter performance. The firm's outlook for 2025 remains optimistic, anticipating further advances in Celldex's pipeline and emphasizing the progress in its current projects.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 11 analysts, the average target price for Celldex Therapeutics Inc (CLDX, Financial) is $60.73 with a high estimate of $90.00 and a low estimate of $36.00. The average target implies an upside of 211.10% from the current price of $19.52. More detailed estimate data can be found on the Celldex Therapeutics Inc (CLDX) Forecast page.
Based on the consensus recommendation from 14 brokerage firms, Celldex Therapeutics Inc's (CLDX, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Celldex Therapeutics Inc (CLDX, Financial) in one year is $18.50, suggesting a downside of 5.23% from the current price of $19.52. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Celldex Therapeutics Inc (CLDX) Summary page.
